Dose‐dependent protective effect of selenium in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences

Normal cellular metabolism produces oxidants that are neutralized within cells by antioxidant enzymes and other antioxidants. An imbalance between oxidant and antioxidant has been postulated to lead the degeneration of dopaminergic neurons in Parkinson's disease. In this study, we examined whether selenium, an antioxidant, can prevent or slowdown neuronal injury in a 6‐hydroxydopamine (6‐OHDA) model of Parkinsonism. Rats were pre‐treated with sodium selenite (0.1, 0.2 and 0.3 mg/kg body weight) for 7 days. On day 8, 2 µL 6‐OHDA (12.5 µg in 0.2% ascorbic acid in normal saline) was infused in the right striatum. Two weeks after 6‐OHDA infusion, rats were tested for neurobehavioral activity, and were killed after 3 weeks of 6‐OHDA infusion for the estimation of glutathione peroxidase, glutathione‐S‐transferase, glutathione reductase, glutathione content, lipid peroxidation, and dopamine and its metabolites. Selenium was found to be successful in upregulating the antioxidant status and lowering the dopamine loss, and functional recovery returned close to the baseline dose‐dependently. This study revealed that selenium, which is an essential part of our diet, may be helpful in slowing down the progression of neurodegeneration in parkinsonism.

[1]  D. Graham,et al.  Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.

[2]  F. Jiménez-Jiménez,et al.  Decreased serum selenium concentrations in patients with Parkinson's disease , 1995, European journal of neurology.

[3]  J. Labandeira-Garcia,et al.  Autoxidation and Neurotoxicity of 6‐Hydroxydopamine in the Presence of Some Antioxidants , 2000, Journal of neurochemistry.

[4]  D. Jollow,et al.  Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. , 1974, Pharmacology.

[5]  T. Dawson.  New Animal Models for Parkinson's Disease , 2000, Cell.

[6]  G. C. Wagner,et al.  Methamphetamine-induced neuronal damage: A possible role for free radicals , 1989, Neuropharmacology.

[7]  P. Riederer,et al.  Oxidative stress: Free radical production in neural degeneration , 1994 .

[8]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[9]  M. Baudry,et al.  Prevention of 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced nitration of tyrosine hydroxylase and neurotoxicity by EUK-134, a superoxide dismutase and catalase mimetic, in cultured dopaminergic neurons , 2000, Brain Research.

[10]  T. Hökfelt,et al.  Autoradiographic demonstration of uptake and accumulation of3H-6-hydroxydopamine in adrenergic nerves , 1971, Experientia.

[11]  P. Sinet,et al.  Hydrogen Peroxide Production by Rat Brain In Vivo , 1980, Journal of neurochemistry.

[12]  Per Brodal,et al.  A stereotaxic atlas of the rat brain L. J. Pellegrino, A. S. Pellegrino & A. J. Cushman. Plenum Press, New York (1979). 122 Figures. £22.50 , 1980, Neuroscience.

[13]  R. Floyd.  Oxidative damage to behavior during aging. , 1991, Science.

[14]  S. Markey,et al.  1-Methyl-4-phenylpyridine (MPP+) induces oxidative stress in the rodent. , 1986, Life sciences.

[15]  U. Ungerstedt,et al.  6-Hydroxy-dopamine induced degeneration of central monoamine neurons. , 1968, European journal of pharmacology.

[16]  C. Marsden,et al.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.

[17]  A. Imperato,et al.  The Antioxidant Ebselen Prevents Neurotoxicity and Clinical Symptoms in a Primate Model of Parkinson's Disease , 2000, Experimental Neurology.

[18]  D. Godin,et al.  Parkinson's disease: A disorder due to nigral glutathione deficiency? , 1982, Neuroscience Letters.

[19]  G. Cohen,et al.  Regional Distribution of Glutathione Peroxidase in the Adult Rat Brain , 1980, Journal of neurochemistry.

[20]  R. Couture,et al.  Mini review: smooth muscle pharmacology of substance P. , 1982, Pharmacology.

[21]  Y. Glinka,et al.  Dopamine Neurotoxicity: Inhibition of Mitochondrial Respiration , 1995, Journal of neurochemistry.

[22]  B. McEwen,et al.  Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra , 1994, Brain Research.

[23]  B. Mannervik,et al.  Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. , 1997, The Biochemical journal.

[24]  G. Bing,et al.  Protection of methamphetamine nigrostriatal toxicity by dietary selenium , 1999, Brain Research.

[25]  Ian Q. Whishaw,et al.  Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats , 1988, Brain Research.

[26]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[27]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[28]  D. Graham.  Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. , 1984, Neurotoxicology.

[29]  J. Barchas,et al.  Simultaneous determination of indole- and catecholamines in tissues using a weak cation-exchange resin. , 1972, Analytical biochemistry.

[30]  B. Mannervik,et al.  Purification and characterization of the flavoenzyme glutathione reductase from rat liver. , 1975, The Journal of biological chemistry.

[31]  Grahame-Smith Dg,et al.  Catecholamine toxicity : a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease , 1984 .

[32]  D. Murphy,et al.  Ferrous‐Citrate Complex and Nigral Degeneration: Evidence for Free‐radical Formation and Lipid Peroxidation a , 1994, Annals of the New York Academy of Sciences.

[33]  M. Youdim.  Iron in the brain: implications for Parkinson's and Alzheimer's diseases. , 1988, The Mount Sinai journal of medicine, New York.

[34]  T. Robinson,et al.  Compensatory changes in striatal dopamine neurons following recovery from injury induced by 6-OHDA or methamphetamine: a review of evidence from microdialysis studies. , 1990, Canadian journal of psychology.

[35]  T. Robinson,et al.  Time course of recovery of extracellular dopamine following partial damage to the nigrostriatal dopamine system , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[36]  P. Jenner,et al.  Understanding cell death in parkinson's disease , 1998, Annals of neurology.

[37]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[38]  J. Cano,et al.  1-Methyl-4-phenylpyridinium has greater neurotoxic effect after selenium deficiency than after vitamin E deficiency in rat striatum. , 1994, European journal of pharmacology.

[39]  J. Salzman,et al.  Automated assays for superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activity. , 1990, Analytical biochemistry.

[40]  G. Breese,et al.  The Use of Neurotoxins to Lesion Catecholamine-Containing Neurons to Model Clinical Disorders , 1998 .

[41]  A. Grace,et al.  Compensations after lesions of central dopaminergic neurons: some clinical and basic implications , 1990, Trends in Neurosciences.

[42]  S. Orrenius,et al.  Calcium ions and oxidative cell injury , 1992, Annals of neurology.

[43]  J. Cadet.  The potential use of vitamin E and selenium in parkinsonism. , 1986, Medical hypotheses.

[44]  C. Fall,et al.  Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. , 1997, Biochimica et biophysica acta.

[45]  H. Ganther,et al.  Selenium: biochemical role as a component of glutathione peroxidase. , 2009, Science.

[46]  D. Kerem,et al.  Effects of dietary supplementation with vitamin E, riboflavin and selenium on central nervous system oxygen toxicity. , 1991, Pharmacology & toxicology.

[47]  M. Sutphin,et al.  Effects of low selenium diets on antioxidant status and MPTP toxicity in mice , 1991, Neurochemical Research.

[48]  J. Coyle,et al.  Oxidative stress, glutamate, and neurodegenerative disorders. , 1993, Science.

[49]  R. Floyd,et al.  Peroxidation induced changes in synaptosomal transport of dopamine and γ-aminobutyric acid , 1989 .

[50]  M. Ebadi,et al.  Oxidative stress and antioxidant therapy in Parkinson's disease , 1996, Progress in Neurobiology.

[51]  A. Slivka,et al.  Hydroxyl radical attack on dopamine. , 1985, The Journal of biological chemistry.

[52]  P Riederer,et al.  The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease. , 1993, Advances in neurology.

[53]  H. Ganther,et al.  Selenium: Biochemical Role as a Component of Glutathione Peroxidase , 1973, Science.

[54]  A. Björklund,et al.  Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease , 2001, European Journal of Neuroscience.

[55]  Barry Halliwell,et al.  Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.

[56]  C. C. Reddy,et al.  Elevation of rat liver mRNA for selenium-dependent glutathione peroxidase by selenium deficiency. , 1990, The Journal of biological chemistry.

[57]  A. Björklund,et al.  Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat , 1996, Neuroscience.

[58]  P. Riederer,et al.  Oxidative stress: free radical production in neural degeneration. , 1994, Pharmacology & therapeutics.

[59]  W. Slikker,et al.  Selenium, an antioxidant, protects against methamphetamine-induced dopaminergic neurotoxicity , 1999, Brain Research.

[60]  R. Floyd,et al.  Free radical damage to protein and DNA: Mechanisms involved and relevant observations on brain undergoing oxidative stress , 1992, Annals of neurology.

[61]  Hyoung-Chun Kim,et al.  Selenium deficiency potentiates methamphetamine-induced nigral neuronal loss; comparison with MPTP model , 2000, Brain Research.

[62]  R. Schwarting,et al.  Relationships between indices of behavioral asymmetries and neurochemical changes following mesencephalic 6-hydroxydopamine injections , 1991, Brain Research.

[63]  C. Dillard,et al.  Measurement of fluorescent lipid peroxidation products in biological systems and tissues. , 1973, Analytical biochemistry.

[64]  K. Yasumoto,et al.  Selenium deficiency as a cause of overload of iron and unbalanced distribution of other minerals. , 1995, Bioscience, biotechnology, and biochemistry.

[65]  M. Roghani,et al.  Neuroprotective effect of vitamin E on the early model of Parkinson’s disease in rat: behavioral and histochemical evidence 1 1 Published on the World Wide Web 3 January 2001. , 2001, Brain Research.

[66]  W B Jakoby,et al.  Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. , 1974, The Journal of biological chemistry.

[67]  F. Gage,et al.  Fibroblast growth factor-2-producing fibroblasts protect the nigrostriatal dopaminergic system from 6-hydroxydopamine , 2000, Brain Research.

[68]  J P Huston,et al.  Behavioral and neurochemical dynamics of neurotoxic meso-striatal dopamine lesions. , 1997, Neurotoxicology.

[69]  J. Glowinski,et al.  Blockade by benzodiazepines of the selective high increase in dopamine turnover induced by stress in mesocortical dopaminergic neurons of the rat , 1979, Brain Research.

[70]  H. Shimasaki.  Assay of fluorescent lipid peroxidation products. , 1994, Methods in enzymology.

[71]  Y. Agid,et al.  Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. , 1973, Nature: New biology.

[72]  J. P. Huston,et al.  The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments , 1996, Progress in Neurobiology.

[73]  J. Cano,et al.  Low Selenium Diet Affects Monoamine Turnover Differentially in Substantia Nigra and Striatum , 1993, Journal of neurochemistry.